Ulipristal
- Generic Name
- Ulipristal
- Brand Names
- Ella, Ellaone, Esmya, ellaOne
- Drug Type
- Small Molecule
- Chemical Formula
- C28H35NO3
- CAS Number
- 159811-51-5
- Unique Ingredient Identifier
- 6J5J15Q2X8
- Background
Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocorticoid receptor, however compared to mif...
- Indication
As the product Ella (available in Canada and the US), ulipristal is indicated for use as emergency contraception after unprotected intercourse or possible contraceptive failure when administered within 120 hours (5 days) after unprotected intercourse or a known or suspected contraceptive failure. As the product Fibristal (available in Canada), ulipristal is ...
- Associated Conditions
- Moderate Uterine Fibroids, Severe Uterine Fibroids
- Associated Therapies
- Emergency Contraception
Ulipristal vs. GnRHa Prior to Laparoscopic Myomectomy
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 100
- Registration Number
- NCT02288130
- Locations
- ๐ณ๐ฑ
Flevoziekenhuis, Almere, Netherlands
๐ณ๐ฑOnze Lieve Vrouwen Gasthuis, Amsterdam, Netherlands
๐ณ๐ฑSint Lucas Andreas Ziekenhuis, Amsterdam, Netherlands
Ulipristal for Endometriosis-related Pelvic Pain
- First Posted Date
- 2014-08-11
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 1
- Registration Number
- NCT02213081
- Locations
- ๐บ๐ธ
Northwestern University, Prentice Women's Hospital, Chicago, Illinois, United States
Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days
- Conditions
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Health Decisions
- Target Recruit Count
- 180
- Registration Number
- NCT01953679
- Locations
- ๐บ๐ธ
University of California, San Francisco, San Francisco, California, United States
๐บ๐ธUniversity of Colorado - Denver Anschutz Medical Campus, Aurora, Colorado, United States
๐บ๐ธEastern Virgina Medical School, Norfolk, Virginia, United States
Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella
- First Posted Date
- 2012-04-03
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- HRA Pharma
- Target Recruit Count
- 98
- Registration Number
- NCT01569737
- Locations
- ๐บ๐ธ
Planned Parenthood Federation of America, Inc, New York, New York, United States
Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- Watson Pharmaceuticals
- Registration Number
- NCT01553123
- Locations
- ๐บ๐ธ
Discovery Clinical Trials - Genesis Health Central Women's Care, Dallas, Texas, United States
๐บ๐ธLawrence Obstetrics-Gynecology Clinical Research, Lawrenceville, New Jersey, United States
๐บ๐ธColumbus Center for Women's Health Research, Columbus, Ohio, United States
Levonorgestrel Intrauterine System For Emergency Contraception
- Conditions
- Interventions
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2024-02-20
- Target Recruit Count
- 274
- Registration Number
- NCT01539720
- Locations
- ๐บ๐ธ
Atlanta Women's Center, Atlanta, Georgia, United States
๐บ๐ธIndiana University School of Medicine, Indianapolis, Indiana, United States
๐บ๐ธWashington University School of Medicine in St. Louis, Saint Louis, Missouri, United States
Ulipristal Acetate on Progesterone Levels and Glycodelin-A Endometrial Pattern
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2011-07-20
- Lead Sponsor
- Programa de Asistencia Reproductiva de Rosario
- Target Recruit Count
- 16
- Registration Number
- NCT01391845
- Locations
- ๐ฆ๐ท
PROAR (Programa de Asistencia Reproductiva de Rosario, Rosario, Santa Fe, Argentina
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.